{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:10:51Z","timestamp":1771481451809,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of the study was to analyze KELIM (modeled CA125 ELIMination rate constant K) and RECIST 1.1. (radiological response valuation criteria in solid tumors) as indicators of tumor chemosensitivity and their role in predicting patient prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center analysis included 165 consecutive patients with advanced newly diagnosed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who underwent surgical and chemotherapeutical treatment at the Department of Gynecologic Oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were significant differences in OS between the neoadjuvant and adjuvant groups of patients (20.87 vs 32.88\u00a0months). There was a significant difference in the response to treatment assessed in imaging studies between the groups, with higher rates of complete and partial responses to treatment among PDS patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). However, upon a separate analysis of the NACT and PDS subgroups, the multivariate analysis showed no significant influence of KELIM and RECIST 1.1. response on patients\u2019 overall survival of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings showed no significant associations between KELIM, RECIST and overall survival of patients. However, further studies on bigger homogenous population samples are required to confirm our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-025-08285-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:16:28Z","timestamp":1771478188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating tumor chemosensitivity: a head-to-head comparison of the prognostic value of KELIM (modeled CA125 elimination rate constant K) and RECIST 1.1 (radiological response valuation criteria in solid tumors) in ovarian cancer"],"prefix":"10.1007","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-681X","authenticated-orcid":false,"given":"Kaja","family":"Michalczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Mokrzycka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Rudzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Misiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Chudecka-G\u0142az","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"8285_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21456","journal-title":"CA Cancer J Clin"},{"key":"8285_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz062","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz062","journal-title":"Ann Oncol"},{"key":"8285_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","volume":"143","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN et al (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. Gynecol Oncol 143:3\u201315. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.022","journal-title":"Gynecol Oncol"},{"key":"8285_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0054","author":"B You","year":"2020","unstructured":"You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE et al (2020) CA-125 ELImination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0054","journal-title":"Clin Cancer Res"},{"key":"8285_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102294","author":"B You","year":"2021","unstructured":"You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E (2021) The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treat Rev. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102294","journal-title":"Cancer Treat Rev"},{"key":"8285_CR6","doi-asserted-by":"crossref","unstructured":"Cohen PA, Powell A, B\u00f6hm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T et al. (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data. Gynecol Oncol, 154","DOI":"10.1016\/j.ygyno.2019.04.679"},{"key":"8285_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039","author":"WT Hwang","year":"2012","unstructured":"Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G (2012) Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2011.09.039","journal-title":"Gynecol Oncol"},{"key":"8285_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0583-5","author":"N Leffers","year":"2009","unstructured":"Leffers N, Gooden MJM, De Jong RA, Hoogeboom BN, Ten Hoor KA, Hollema H, Boezen HM, Van Der Zee AGJ, Daemen T, Nijman HW (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-008-0583-5","journal-title":"Cancer Immunol Immunother"},{"key":"8285_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2102","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA et al (2020) ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2102","journal-title":"Ann Oncol"},{"key":"8285_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1456","author":"D Yang","year":"2011","unstructured":"Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. https:\/\/doi.org\/10.1001\/jama.2011.1456","journal-title":"JAMA"},{"key":"8285_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000480","author":"B Pellegrino","year":"2019","unstructured":"Pellegrino B, Mateo J, Serra V, Balma\u00f1a J (2019) Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2018-000480","journal-title":"ESMO Open"},{"key":"8285_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.625866","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang X, Gao Y, Shang C, Yu B, Wang T, Su J, Huang C, Wu Y, Guo H et al (2021) Development of a genomic signatures-based predictor of initial platinum-resistance in advanced high-grade serous ovarian cancer patients. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.625866","journal-title":"Front Oncol"},{"key":"8285_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1874-9","author":"J Sun","year":"2019","unstructured":"Sun J, Bao S, Xu D, Zhang Y, Su J, Liu J, Hao D, Zhou M (2019) Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-019-1874-9","journal-title":"Cell Death Dis"},{"key":"8285_CR14","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2011.22.3.183","author":"J Menczer","year":"2011","unstructured":"Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T (2011) Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2011.22.3.183","journal-title":"J Gynecol Oncol"},{"key":"8285_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2019.04.007","author":"G Bogani","year":"2019","unstructured":"Bogani G, Matteucci L, Tamberi S, Ditto A, Sabatucci I, Murgia F, Arcangeli V, Maltese G, Comerci G, Stefanetti M et al (2019) RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. Eur J Obstet Gynecol Reprod Biol. https:\/\/doi.org\/10.1016\/j.ejogrb.2019.04.007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"8285_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.05.013","author":"B You","year":"2013","unstructured":"You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K et al (2013) The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.013","journal-title":"Gynecol Oncol"},{"key":"8285_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.002","author":"ML Pearl","year":"2015","unstructured":"Pearl ML, Dong H, Tulley S, Zhao Q, Golightly M, Zucker S, Chen WT (2015) Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (ICTCs). Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.002","journal-title":"Gynecol Oncol"},{"key":"8285_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002198","author":"CA Parkinson","year":"2016","unstructured":"Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K et al (2016) Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. https:\/\/doi.org\/10.1371\/journal.pmed.1002198","journal-title":"PLoS Med"},{"key":"8285_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-5335-0","author":"Y Shen","year":"2016","unstructured":"Shen Y, Li L (2016) Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumor Biol. https:\/\/doi.org\/10.1007\/s13277-016-5335-0","journal-title":"Tumor Biol"},{"key":"8285_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.031","author":"RG Moore","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2008.08.031","journal-title":"Gynecol Oncol"},{"key":"8285_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2017.04.014","author":"G Danala","year":"2017","unstructured":"Danala G, Thai T, Gunderson CC, Moxley KM, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y (2017) Applying quantitative CT image feature analysis to predict response of ovarian cancer patients to chemotherapy. Acad Radiol. https:\/\/doi.org\/10.1016\/j.acra.2017.04.014","journal-title":"Acad Radiol"},{"key":"8285_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.800547","author":"L Fournier","year":"2022","unstructured":"Fournier L, de Geus-Oei LF, Regge D, Oprea-Lager DE, D\u2019Anastasi M, Bidaut L, B\u00e4uerle T, Lopci E, Cappello G, Lecouvet F et al (2022) Twenty years on: RECIST as a biomarker of response in solid tumours an EORTC imaging group \u2013 ESOI joint paper. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.800547","journal-title":"Front Oncol"},{"key":"8285_CR23","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v8.i5.513","author":"SH Chandrashekhara","year":"2016","unstructured":"Chandrashekhara SH, Triveni GS, Kumar R (2016) Imaging of peritoneal deposits in ovarian cancer: a pictorial review. World J Radiol. https:\/\/doi.org\/10.4329\/wjr.v8.i5.513","journal-title":"World J Radiol"},{"key":"8285_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"8285_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(16)30387-2","author":"I Teslenko","year":"2015","unstructured":"Teslenko I, Belotserkovsky M (2015) 717 common pitfalls of RECIST 1.1 application in clinical trials. Eur J Cancer. https:\/\/doi.org\/10.1016\/s0959-8049(16)30387-2","journal-title":"Eur J Cancer"},{"key":"8285_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3335","author":"O Colomban","year":"2019","unstructured":"Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Bois AD, Kurzeder C, Burges A et al (2019) Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU study. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3335","journal-title":"Clin Cancer Res"},{"key":"8285_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/JNCICS\/PKAA026","author":"O Colomban","year":"2021","unstructured":"Colomban O, Tod M, Peron J, Perren TJ, Leary A, Cook AD, Sajous C, Freyer G, You B (2021) Bevacizumab for newly diagnosed ovarian cancers: best candidates among high-risk disease patients (Icon-7). JNCI Cancer Spectr. https:\/\/doi.org\/10.1093\/JNCICS\/PKAA026","journal-title":"JNCI Cancer Spectr"},{"key":"8285_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.986","author":"L Van Wagensveld","year":"2020","unstructured":"Van Wagensveld L, Colomban O, Van Der AA M, Tod M, Sonke GS, Kruitwagen R, You B (2020) 847P the prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.986","journal-title":"Ann Oncol"},{"key":"8285_CR29","doi-asserted-by":"crossref","unstructured":"You B, Fleming G, Bookman M, Moore K, Steffensen K, Coleman R (2020) 36 prognostic value and association with veliparib benefit of modeled CA-125 Elimination Kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA\/GOG-3005 study","DOI":"10.1136\/ijgc-2020-IGCS.36"},{"key":"8285_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz250.035","author":"O Colomban","year":"2019","unstructured":"Colomban O, Tod M, Leary A, Ray-Coquard IL, Lortholary A, Hardy-Bessard A-C, Pfisterer J, Du Bois A, Kurzeder C, Burges A et al (2019) Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO\/GINECO\/ MRC CTU\/GCIG trials). Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz250.035","journal-title":"Ann Oncol"},{"key":"8285_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ygyno.2024.04.009","volume":"187","author":"S Piedimonte","year":"2024","unstructured":"Piedimonte S, Murray C, Atenafu EG, Rouzbahman M, Lheureux S, May T (2024) Correlating the KELIM (CA125 Elimination Rate Constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma. Gynecol Oncol 187:92\u201397. https:\/\/doi.org\/10.1016\/j.ygyno.2024.04.009","journal-title":"Gynecol Oncol"},{"key":"8285_CR32","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1200\/jco.2024.42.16_suppl.5560","volume":"42","author":"B You","year":"2024","unstructured":"You B, Fagotti A, Colomban O, Giannarelli D, Blanc-Durand F, Scambia G, Carrot A, Lorusso D, Pujade-Lauraine E, Ergasti R et al (2024) Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets. J Clin Oncol 42:5560\u20135560. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.5560","journal-title":"J Clin Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08285-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-025-08285-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08285-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:16:30Z","timestamp":1771478190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-025-08285-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8285"],"URL":"https:\/\/doi.org\/10.1007\/s00404-025-08285-z","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}